The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens

Mariya Huralska; Jason M. Pogue; Michael J. Rybak; Jacinda C. Abdul‐Mutakabbir; Kyle Stamper; Dror Marchaim; Visanu Thamlikitkul; Yehuda Carmeli; Cheng‐Hsun Chiu; George L. Daikos; Sorabh Dhar; Emanuele Durante‐Mangoni; Achilleas Gikas; Αναστασία Κοτανίδου; Mical Paul; Emmanuel Roilides; Michael Samarkos; Matthew Sims; Dora Tancheva; Sotirios Tsiodras; Daniel H. Kett; Gopi Patel; David P. Calfee; L. Leibovici; L. Power; L. Silvia Muñoz-Price; Hamadullah Shaikh; Laura Susick; Katie Latack; Christine C. Chiou; George Divine; Varduhi Ghazyaran; Keith S. Kaye

doi:10.1093/cid/ciaf398

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Colistin-based, synergistic combination treatment with meropenem (compared to nonsynergistic colistin-based therapy) was associated with decreased clinical failure, particularly in people with pneumonia and A. baumannii.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Huralska et al. (2025) studied this question.

synapsesocial.com/papers/69dbdf80eb8801008ea3c0e1 https://doi.org/10.1093/cid/ciaf398

View Full Paper

Ask AI

Bookmark

Share

The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens

Ask about this paper

Abstract

Discussion

Cite This Study

The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading